A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
Publication - published on 24 Nov 2020

Materiality of Superbugs

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimicrobial resistance (AMR). If left unchecked, AMR is set to substantially undermine the global economy’s financial recovery and future outlook. Here, Mara Lilley and Sana Johnson run through the main risks and opportunities presented by superbugs for pharma companies and resources available for navigating through them.

The viewpoint covers:

  • Why antimicrobial resistance (AMR) is a material issue for investors in pharmaceutical companies.
  • The main risks and opportunities presented by superbugs for pharma companies.
  • Resources available for investors to navigate through these risks and steer better outcomes.
  • How the Access to Medicine Foundation supports investor leadership in the fight against superbugs through the Investor Action on AMR initiative.

The issues were discussed in a virtual event organised by the Investor Action on AMR Initiative, which is jointly coordinated by the Access to Medicine Foundation, the FAIRR Initiative, the UK Department of Health & Social Care, and the Principles for Responsible Investment (PRI). Watch the event here.  

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |